AGEN 1571
Alternative Names: AGEN-1571Latest Information Update: 03 Aug 2022
Price :
$50 *
At a glance
- Originator Agenus
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Leukocyte immunoglobulin-like receptor B1 inhibitors; Natural killer cell stimulants; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Solid tumours
Most Recent Events
- 19 Jul 2022 Phase-I clinical trials in Solid tumours (Combination therapy, Late-stage disease, Metastatic disease) in USA (IV) (NCT05377528)
- 19 Jul 2022 Phase-I clinical trials in Solid tumours (Late-stage disease, Metastatic disease, Monotherapy) in USA (IV) (NCT05377528)
- 08 Apr 2022 Pharmacokinetics data from a preclinical trial in cancer presented at the 113th Annual Meeting of the American Association for Cancer Research (AACR-2022)